Global Cancer Immunotherapy Market & Cancer Immunotherapy Clinical Trials Outlook 2022

Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics.

Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being made due to which development of worthy candidates with high commercialization and pharmacological potential is expected to increase in coming years.

Several cancer immunotherapies have been widely accepted by both physicians and patients as a result their demand in global market is expected to increase. In this way, more innovative cancer immunotherapy products are expected to enter in global market in next few years.

Investigators are trying to decipher underlying principle of cancer progression and proliferation. Different cancer indications have different requirements for developing effective therapeutics due to which identification of these factors have become important. This knowledge would be used for developing innovative cancer immunotherapies for various malignancies.

Cancer immunotherapeutics based on these discoveries would pave path for market introduction of highly effective therapeutics. Some progress has been made which could be noticed by observing plethora of cancer immunotherapeutics available for different cancer indications. Their clinical pipeline is also developing rapidly and various products are at different stages of clinical trials. They are expected to offer severe competition to presently available cancer therapeutics with modest pharmacological efficacy.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-cancer-immunotherapy-market-and-clinical-trials-outlook-2022.php

Report Table of Contents

1. Immunotherapy: Mending Cancer Regimens
1.1 Preface to Cancer Immunotherapy
1.2 Evolution of Cancer Immunotherapy

2. Categorization of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors

3. Fundamentals of Cancer Vaccines
3.1 Prologue of Cancer Vaccines
3.2 Cancer Vaccines in Immunotherapy
3.3 Commercial Aspects of Cancer Vaccines

4. New Era of Monoclonal Antibodies
4.1 Rudiments of Monoclonal Antibodies
4.2 Advents of Monoclonal Antibodies
4.3 Commercial Aspects of Monoclonal Antibodies

5. Trails of T-Cell Therapies
5.1 Adoptive Cell Transfer Technology
5.2 Strategies of Adoptive Cell Transfer
5.3 Commercial Aspects of Adoptive Cell Therapy

6. Aspects of Immune Checkpoint Inhibitors
6.1 Prelude to Immune Checkpoint Inhibitors
6.2 Implications of Immunecheck Point Inhibitors
6.3 Commercial Aspects of Immune Checkpoint Inhibitors

7. Immunomodulators in Cancer Immunotherapy
7.1 Perspective of Immunomodulators
7.2 Clinical Aspects of Immunomodulators
7.3 Commercial Aspects of Immunomodulators

8. Oncolytic Viral Immunotherapy
8.1 Concept to Oncolytic Viruses
8.2 Potential Approaches of Oncolytic Viruses
8.3 Commercial Aspects of Oncolytic Viruses

9. Cytokines in Cancer Immunotherapy
9.1 Fundamentals of Cytokines
9.2 Classification of Cytokines
9.3 Commercial Aspects of Cytokines

10. Interferons in Immunotherapy
10.1 Potentials of Interferons
10.2 Classification of Interferons
10.3 Clinical Applications of Interferons

11. Interleukins in Immunotherapy
11.1 Potentials of Interleukins
11.2 Clinical Applications of Interleukins

12. GM-CSF in Immunotherapy
12.1 Potentials of GM-CSF
12.2 Clinical Applications of GM-CSF

13. Global Economic Evaluations
13.1 Economic Aspects of Cancer Immunotherapy
13.2 Cancer Immunotherapy Cost by Product

14. Market Aspects of Cancer Immunotherapy
14.1 Current Market Trends
14.2 Cancer Immunotherapy Pipeline Overview

15. Global Cancer Immunotherapy Market Dynamics
15.1 Favorable Market Parameters
15.2 Commercialization Challenges

16. Marketed Cancer Cell Therapies Drugs
16.1 Sipuleucel-T (Provengeandreg;)
16.2 T-Lymphocyte Cell Therapy(Immuncell-LCandreg;)

17. Marketed Cancer Cytokines Drugs
17.1 Aldesleukin (Proleukinandreg;)
17.2 Denileukin Diftitox (ONTAKandreg;)
17.3 Interferon Alpha (Multiferonandreg;)
17.4 Interferon Alpha-2a (Roferon-Aandreg;)
17.5 Interferon Alpha-2a (Veldonaandreg;)
17.6 Interferon Alpha-2a Biosimilar(Inferonandtrade;/Inmutagandtrade;)
17.7 Interferon Alpha-2b(Intronandreg; A)
17.8 Interferon Alpha-2b Biosimilar(Bioferonandtrade;)
17.9 Interferon Alpha-2b Biosimilar (Intalfaandreg;)
17.10 Interferon Alpha-2b Biosimilar
17.11 Interferon-Alpha-n3 (Alferon Nandreg;)
17.12 Interferon-Beta-1b (Feronandreg;)
17.13 Interferon-Gamma (Ogammaandreg;)
17.14 Interleukin-2 Biosimilar (Ilcass)
17.15 Teceleukin (Imunaceandtrade;)

18. Marketed Cancer Vaccines
18.1 Bladder Cancer Vaccine (PACISandreg;)
18.2 Bladder Cancer Vaccine
18.3 BV NSCLC 001
18.4 Dendritic Cell Vaccine (CreaVax-HCCandreg;, CreaVax-PCandreg; and CreaVax-RCCandreg;)
18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasilandreg;/Silgardandreg;)
18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarixandreg;)
18.7 Melanoma Vaccine (MVaxandreg;)
18.8 Melanoma Vaccine (Melacineandreg;)
18.9 Racotumomab (Vaxiraandreg;)
18.10 Sipuleucel-T (Provengeandreg;)
18.11 Tertomotide (LucaVax)
18.12 Vitespen (Oncophageandreg;)

19. Marketed Cancer Monoclonal Antibodies
19.1 Bevacizumab
19.2 Trastuzumab Emtansine
19.3 Trastuzumab Subcutaneous
19.4 Brentuximab Vedotin
19.5 Catumaxomab
19.6 Ipilimumab
19.7 Nivolumab
19.8 Pembrolizumab
19.9 Pertuzumab
19.10 Rituximab
19.11 Trastuzumab

20. Global Cancer Immunotherapy Market Future Prospects

21. Competitive Landscape
21.1 Abbvie
21.2 Advaxis
21.3 Altor BioScience
21.4 Amgen
21.5 Biogen Idec
21.6 Biogenomics
21.7 Celldex Therapeutics
21.8 Dendreon Corporation
21.9 Eli Lilly
21.10 Expression Genetics
21.11 Galena Biopharma
21.12 Genmab
21.13 Gilead Sciences
21.14 GlaxoSmithKline
21.15 ImmunoCellular Therapeutics
21.16 ImmunoGen
21.17 Inovio Pharmaceuticals
21.18 IRX Therapeutics
21.19 Merck
21.20 NeoStem Oncology
21.21 NewLink Genetics
21.22 Northwest Biotherapeutics
21.23 Novartis
21.24 Peregrine Pharmaceuticals
21.25 Pfizer
21.26 Philogen
21.27 Regulon
21.28 Roche
21.29 Seattle Genetics
21.30 ZymoGenetics

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.